aTyr Pharma (LIFE) News Today → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free LIFE Stock Alerts $1.73 -0.03 (-1.70%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | marketbeat.comShort Interest in aTyr Pharma, Inc. (NASDAQ:LIFE) Declines By 46.0%aTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 343,400 shares, a decline of 46.0% from the April 30th total of 636,200 shares. Based on an average trading volume of 563,900 shares, the short-interest ratio is presently 0.6 days.May 25, 2024 | finanznachrichten.deaTyr Pharma, Inc.: aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 24, 2024 | globenewswire.comaTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 15, 2024 | finance.yahoo.comaTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International ConferenceMay 15, 2024 | globenewswire.comaTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International ConferenceMay 14, 2024 | globenewswire.comaTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisMay 12, 2024 | marketbeat.comaTyr Pharma, Inc. (NASDAQ:LIFE) Short Interest UpdateaTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) was the target of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 636,200 shares, a growth of 66.1% from the April 15th total of 383,100 shares. Based on an average daily volume of 572,400 shares, the short-interest ratio is currently 1.1 days.May 3, 2024 | markets.businessinsider.comStrong Buy Rating for aTyr Pharma as Efzofitimod Shows Promise and Financial StabilityMay 3, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on aTyr Pharma (LIFE)May 3, 2024 | marketbeat.comaTyr Pharma's (LIFE) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of aTyr Pharma in a research note on Friday.May 3, 2024 | marketbeat.comaTyr Pharma (NASDAQ:LIFE) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPSaTyr Pharma (NASDAQ:LIFE - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.11 million.May 2, 2024 | investorplace.comLIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | globenewswire.comaTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateApril 21, 2024 | finance.yahoo.comaTyr Pharma Insiders Placed Bullish Bets Worth US$514.6kApril 17, 2024 | msn.comAtal Incubation Centre - Centre for Cellular and Molecular Biology signs agreement with Thermo Fisher Scientific to advance innovation in IndiaApril 9, 2024 | marketbeat.comaTyr Pharma, Inc. (NASDAQ:LIFE) Shares Sold by Stonepine Capital Management LLCStonepine Capital Management LLC lowered its position in aTyr Pharma, Inc. (NASDAQ:LIFE - Free Report) by 89.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 482,258 shares of the biotechnologyApril 1, 2024 | finance.yahoo.comaTyr Pharma to Participate in April Investor ConferencesApril 1, 2024 | globenewswire.comaTyr Pharma to Participate in April Investor ConferencesMarch 28, 2024 | marketbeat.comShort Interest in aTyr Pharma, Inc. (NASDAQ:LIFE) Rises By 167.4%aTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 289,300 shares, an increase of 167.4% from the February 29th total of 108,200 shares. Based on an average daily volume of 521,200 shares, the short-interest ratio is currently 0.6 days.March 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 18, 2024 | marketbeat.comaTyr Pharma (NASDAQ:LIFE) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of aTyr Pharma in a research report on Friday.March 18, 2024 | marketbeat.comRoyal Bank of Canada Cuts aTyr Pharma (NASDAQ:LIFE) Price Target to $16.00Royal Bank of Canada reduced their target price on aTyr Pharma from $19.00 to $16.00 and set an "outperform" rating on the stock in a report on Friday.March 18, 2024 | msn.com3 Best Stocks to Buy Now, 3/18/2024, According to Top AnalystsMarch 17, 2024 | finanznachrichten.deaTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateMarch 16, 2024 | benzinga.comRecap: aTyr Pharma Q4 EarningsMarch 16, 2024 | finance.yahoo.comaTyr Pharma Full Year 2023 Earnings: Revenues DisappointMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for aTyr Pharma as Lead Candidate efzofitimod Advances in Clinical Trials with Solid Financial FootingMarch 15, 2024 | finance.yahoo.comaTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate ProgressMarch 15, 2024 | finance.yahoo.comQ4 2023 aTyr Pharma Inc Earnings CallMarch 15, 2024 | finance.yahoo.comaTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | investorplace.comLIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023March 14, 2024 | washingtonpost.comAtyr Pharma: Q4 Earnings SnapshotMarch 14, 2024 | globenewswire.comaTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateMarch 14, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 14, 2024March 13, 2024 | benzinga.comaTyr Pharma's Earnings OutlookMarch 13, 2024 | markets.businessinsider.comaTyr Pharma is about to announce earnings — here's what Wall Street expectsMarch 5, 2024 | marketbeat.comaTyr Pharma (NASDAQ:LIFE) Stock Crosses Above 200 Day Moving Average of $1.51aTyr Pharma (NASDAQ:LIFE) Share Price Crosses Above 200 Day Moving Average of $1.51February 28, 2024 | globenewswire.comaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsFebruary 23, 2024 | finance.yahoo.comWe Think aTyr Pharma (NASDAQ:LIFE) Can Afford To Drive Business GrowthFebruary 21, 2024 | finance.yahoo.comaTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsFebruary 21, 2024 | marketbeat.comaTyr Pharma (NASDAQ:LIFE) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and set a $35.00 price target on shares of aTyr Pharma in a research note on Wednesday.February 21, 2024 | globenewswire.comaTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsFebruary 20, 2024 | marketbeat.comaTyr Pharma (NASDAQ:LIFE) Shares Pass Above 200 Day Moving Average of $1.51aTyr Pharma (NASDAQ:LIFE) Share Price Crosses Above 200 Day Moving Average of $1.51February 20, 2024 | marketbeat.comaTyr Pharma, Inc. (NASDAQ:LIFE) Given Average Recommendation of "Moderate Buy" by BrokeragesaTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. ThFebruary 15, 2024 | investorplace.comThe 3 Best Penny Stocks to Buy in February 2024February 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), CVS Health (CVS) and Science 37 (SNCE)February 7, 2024 | marketbeat.comaTyr Pharma (NASDAQ:LIFE) Stock Price Crosses Above 200 Day Moving Average of $1.52aTyr Pharma (NASDAQ:LIFE) Share Price Passes Above 200 Day Moving Average of $1.52February 3, 2024 | finance.yahoo.comAfter losing 23% in the past year, aTyr Pharma, Inc. (NASDAQ:LIFE) institutional owners must be relieved by the recent gainJanuary 30, 2024 | marketbeat.comaTyr Pharma, Inc. (NASDAQ:LIFE) Sees Significant Drop in Short InterestaTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 177,500 shares, a decline of 16.3% from the December 31st total of 212,100 shares. Based on an average trading volume of 344,200 shares, the days-to-cover ratio is currently 0.5 days.January 29, 2024 | finance.yahoo.comaTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter. Email Address The Worst is Yet to Come… (Ad)Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly. Click here to stream this controversial exposé now. LIFE Media Mentions By Week LIFE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIFE News Sentiment▼1.310.76▲Average Medical News Sentiment LIFE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIFE Articles This Week▼31▲LIFE Articles Average Week Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Harvard Bioscience News Today PTC Therapeutics News Today Sarepta Therapeutics News Today Thermo Fisher Scientific News Today Agilent Technologies News Today Mettler-Toledo International News Today Waters News Today Illumina News Today Bio-Techne News Today Bruker News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIFE) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
